You’re Seeing Trial Risk Too Late

Most signals show up once the study is underway. By then, teams are reacting to issues that have been building for weeks.

What if you could identify risk during site initiation instead?

Join our fireside chat at the Precision in Clinical Trials Summit or schedule a 1:1 meeting to explore how measuring readiness during site initiation reveals risk earlier.

Schedule Time in Boston
Save Your Spot at PCT
PCT 2026 LI Image

We’ve Improved Risk Detection. Not Timing

Most trial teams have invested heavily in RBQM. But the signals it generates usually show up once the study is underway.
By then, teams are reacting to issues that have been building for weeks.
Early Risk Signal Timeline
 
Risk doesn’t start downstream in the data. It starts with human variability.

Differences in how sites interpret and execute the protocol matter more than most teams realize. That variability is measurable, and it shows up before the study starts.

Measuring readiness during site activation creates an early warning signal that allows teams to act sooner.

As outlined in a recent Applied Clinical Trials article, measuring readiness during training can reveal risk before it shows up in trial data.

PCT Summit Fireside Chat_Boston 2026

Join the Conversation at PCT Boston

We’re still identifying trial risk after it’s already impacting execution.

This session focuses on a different approach. Measuring readiness during site initiation to surface risk earlier, before first patient in and before performance starts to drift.

 

Save Your Spot →

We’ll be continuing these conversations throughout PCT.

Let’s Meet in Boston

We’ll be meeting with clinical and operational leaders throughout PCT.

If you’re rethinking how your team identifies and manages execution risk, we’d welcome the conversation.

Request a Meeting